Timolol plus maximum tolerated antiglaucoma therapy: a one-year followup study.
Thirty-three eyes of 22 patients with primary open-angle glaucoma or severe ocular hypertension had topical timolol maleate added to their maximally tolerated medical regimens. With minimal side effects, 25 eyes (76%) could be treated medically for one year, and only eight eyes (24%) required filtering surgery. Thirteen (39%) of the medically treated eyes achieved intraocular pressures of 21 mm Hg or less. After the addition of timolol, 17 of the 33 eyes (52%) completed the one-year protocol with final mean intraocular pressure decreases of 5 mm Hg or more on medical therapy.
D000368:Aged; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007498:Iris / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010277:Parasympathomimetics / Q000008:administration & dosage; D011412:Propanolamines / Q000627:therapeutic use*; D013566:Sympathomimetics / Q000008:administration & dosage; D013997:Time Factors; D013999:Timolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D002257:Carbonic Anhydrase Inhibitors; D010277:Parasympathomimetics; D011412:Propanolamines; D013566:Sympathomimetics; D013999:Timolol